Nouscom

Race for the Cure is a vibrant fundraising initiative dedicated to raise awareness and funds for cancer research and support programs. Nouscom is  proud to support the fight against breast cancer and race as a team alongside the WOMEN IN PINK on May 12th. Join the Nouscom team at Race For The Cure ROME, Circo Massimo #raceforthecure #againstbreastcancer #thinkpink #nouscom

Lynch Syndrome Awareness Day (22nd March)   Today is Lynch Syndrome Awareness Day. Despite being the most common inherited cancer syndrome, join us as we shed light on this under diagnosed condition.   Lynch Syndrome is a genetic disorder that increases the risk to certain cancers, particularly colorectal and endometrial cancers. It is estimated that 1 in 300 people have Lynch Syndrome, but that less than 10% are aware they are a carrier. It is crucial to be aware if you have Lynch Syndrome and undergo regular screening as early detection of cancer saves lives.   At Nouscom, we believe that raising awareness of Lynch Syndrome will encourage wider diagnosis and regular screening, and it is our mission to develop an effective therapy that is able to intercept the development of Lynch Syndrome related cancers.   Learn more about our work here: https://www.nouscom.com/   #LynchSyndromeDay #Healthcareawareness #EarlyDetection #PatientCare  

https://lnkd.in/eFTZCBBW #seriesC #financing #neoantigens #cancervaccine #nouscom #clinicaldata

Colorectal Cancer Awareness Month (March, Dress in Blue day 1st March) The 1st of March marks the beginning of National Colorectal Cancer Awareness month and Dress in Blue Day. Join us in raising awareness and wearing blue to join the global mission to end colorectal cancer.   Colorectal cancer is among the most underfunded areas of cancer research, despite being the number one deadliest cancer for men and the second deadliest cancer for women. Through regular screening and early identification, colorectal cancer can be successfully treated before it develops.   We believe that awareness and greater understanding of colorectal cancer helps boost the chances of patients obtaining early cancer diagnosis, and it is our mission for the benefit of patients to develop effective treatments for colorectal cancer. Learn more about our work here: https://www.nouscom.com/   Find out more about #ColorectalCancerAwarenessMonth: https://lnkd.in/e-CzxNUa   #colorectalcancer #cancerawareness #cancerprevention #screeningsaveslives 

We are pleased to announce our newest publication titled “Tumor burden dictates the neoantigen features required to generate an effective cancer vaccine” on CIR (https://lnkd.in/eMkyFK2c). We demonstrate that whilst multiple neoantigens in combination with checkpoint inhibitors are needed for efficacy in high disease burden settings, single epitopes can be effective in early disease burden models. To achieve effective and durable responses does require a platform with sufficient neoantigen capacity that is able to promote CD4 and CD8 T cell responses and epitope spreading. #cancervaccines #neoantigens #viralvectors #immunotherapy

Nouscom Raises €67.5 million ($72 million) in Series C Financing Round. We are thrilled to welcome new investors join our existing investors to enable us to continue advancing the clinical development of our portfolio of neoantigen cancer vaccines to key clinical proof of concept readouts. View the press release: https://lnkd.in/ekmjCAmv #seriesC #financing #neoantigens #cancervaccine #nouscom #clinicaldata 

Nouscom is excited to participate in the Jefferies London Healthcare Conference where we will meet with investors and potential partners to share exciting corporate developments and progress of our clinical pipeline. The event takes place November 14-16. #JefferiesHealthcare

We are pleased to announce the publication of a late-breaking abstract on the potential of Nouscom’s Off-the-Shelf Cancer Vaccine, NOUS-209, to ‘Intercept’ Cancer in Subjects with Lynch Syndrome. The abstract will be presented in an oral abstract presentation on 4th November 2023 at the Society for Immunotherapy of Cancer (SITC) Annual Meeting in San Diego, USA. View the press release: https://lnkd.in/eG775TE9

Proud to announce that from over 1600 submitted abstracts, Nouscom are one of only a handful of abstracts selected for a Late-Breaking Oral presentation at the Society for Immunotherapy of Cancer (SITC) for Immunotherapy of Cancer (SITC) 38th annual meeting, 1 - 5th November in San Diego, CA. View the Title and Authors here: https://lnkd.in/eADA7Q7C #SITC23 #oncology #clinicaltrial #immunotherapy